P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer
NCT ID: NCT05542940
Last Updated: 2022-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2020-01-01
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients and methods:
100 cases of endometrial cancer will be included in the study, recruited from Alexandria university hospital gyne-oncology unit. Surgical staging, histopathological examination and immunohistochemistry of p53 were done to all cases to calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types, grading.
Keywords: P53 immunohistochemistry, endometrial cancer, clinicopathological relation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53
NCT05755893
Molecular Classification of Endometrial Cancer: Impact on Adjuvant Treatment Planning.
NCT06584630
"Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients"
NCT06759714
Cancer Survivorship in Hematologic Malignancies
NCT05780411
Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma
NCT06521684
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading
p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hossam Hassan Aly Hassan El Sokkary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hossam Hassan Aly Hassan El Sokkary
Associate professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hossam Hassan El Sokkary
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SOKKARY9
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.